Loading...
•
Dec 31, 2024
Cerus Q4 2024 Earnings Report
Cerus Corporation announced its full-year and fourth quarter 2024 financial results, with product revenues increasing by 9% from the prior year period for the fourth quarter and 15% for the full year. The company also reported its fourth straight quarter of positive operating cash flows.
Key Takeaways
Cerus Corporation delivered strong financial results for the fourth quarter and full year 2024, exceeding its stated goals. Product revenue grew significantly, driven by momentum in its platelets business and increasing demand for its IFC product. The company achieved positive non-GAAP adjusted EBITDA and generated substantial positive operating cash flows, demonstrating robust financial execution.
Fourth quarter 2024 product revenue increased by 9% year-over-year to $50.8 million.
The company achieved positive non-GAAP adjusted EBITDA of $3.3 million for Q4 2024 and $5.7 million for FY 2024, outperforming its break-even objective.
Cerus generated positive operating cash flows for the fourth consecutive quarter, reaching $4.9 million in Q4 2024 and $11.4 million for FY 2024.
Net loss attributable to Cerus Corporation improved significantly to $2.5 million in Q4 2024 and $20.9 million for FY 2024, compared to prior year periods.
Cerus
Cerus
Cerus Revenue by Segment
Cerus Revenue by Geographic Location
Revenue by Segment
Product Revenue
CapyFin.comGovernment Contract Revenue
CapyFin.comRevenue by Geographic Location
North America Revenue
CapyFin.comEurope, Middle East and Africa Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Cerus Corporation reiterated its full-year 2025 annual product revenue guidance to be in the range of $194 million to $200 million, representing 8% to 11% growth from 2024. This guidance includes $12 million to $15 million for INTERCEPT Fibrinogen Complex (IFC) revenue.
Positive Outlook
- Continued penetration with U.S. platelet customers is expected to fuel product revenue growth.
- Geographic expansion of the INTERCEPT platelet business is anticipated to contribute to revenue growth.
- Increasing uptake of INTERCEPT Fibrinogen Complex (IFC) in the U.S. is a key growth driver.
- The company expects improvements to GAAP net loss attributable to Cerus Corporation for full-year 2025.
- Cerus aims to maintain a positive non-GAAP adjusted EBITDA for full-year 2025.
Challenges Ahead
- Risks associated with the commercialization and market acceptance of the INTERCEPT Blood System.
- Uncertainty regarding the volume or timing of commercial purchases from U.S. customers.
- Potential inability to effectively expand commercialization activities into additional geographies or realize revenue from new product offerings.
- Macroeconomic developments, including military conflicts, tariffs, and trade tensions, could negatively impact business operations.
- Risks related to maintaining an effective and qualified U.S.-based commercial organization and achieving market acceptance in the U.S.
Revenue & Expenses
Visualization of income flow from segment revenue to net income